Daiichi Sankyo
DSKYFNext catalyst
Trastzumab Deruxtecan
Ovarian Cancer
Get an email about DSKYF's next catalysts
Track Daiichi Sankyo (DSKYF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 19 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
20 upcoming, 0 past
Trastzumab Deruxtecan Phase 2 Est. Readout (TROY)
Estimated primary completion for Trastzumab Deruxtecan trial (NCT07340164) in Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourceTrastuzumab Deruxtecan Phase 2 Est. Readout
Estimated primary completion for Trastuzumab Deruxtecan trial (NCT04553770) in Early-stage Breast Cancer. Topline data typically follows completion by weeks to months.
SourceDato-DXd Phase 3 Est. Readout (TROPION-Lung15)
Estimated primary completion for Dato-DXd trial (NCT06417814) in Metastatic Non-small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceDS-5141b Phase 2 Est. Readout
Primary completion for DS-5141b trial (NCT04433234) in Duchenne Muscular Dystrophy
SourceTrastuzumab deruxtecan Phase 2 Est. Readout
Estimated primary completion for Trastuzumab deruxtecan trial (NCT06271837) in Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer). Topline data typically follows completion by weeks to months.
SourceTrastuzumab deruxtecan Phase 2 Est. Readout (DPT02)
Estimated primary completion for Trastuzumab deruxtecan trial (NCT04482309) in Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer. Topline data typically follows completion by weeks to months.
SourceU3-1402 Phase 2 Est. Readout (ICARUS BREAST)
Estimated primary completion for U3-1402 trial (NCT04965766) in Metastatic Breast Cancer. Topline data typically follows completion by weeks to months.
SourceIfinatamab deruxtecan (I-DXd) Phase 2 Est. Readout
Primary completion for Ifinatamab deruxtecan (I-DXd) trial (NCT04145622) in Advanced Solid Tumor
SourceHow DSKYF's past catalysts played out
Market Overview
Stock performance and key metrics
Salvage Chemotherapy
AML
olmesartan medoxomil + amlodipine + hydroclororthiazide
Essential Hypertension
OLM -AML -Hydrochlorothiazide
Essential Hypertension
Olmesartan -Amlodipine -Hydrochlorothiazide
Essential Hypertension
cevimeline hydrochloride
Head and Neck Cancer
low molecular weight heparin/unfractionated heparin
Venous Thromboembolism
enoxaparin sodium
Venous Thromboembolism
CHS-0214
Rheumatoid Arthritis
T-DXd
Advanced Cancer
Rivoglitazone
Type 2 Diabetes
Tivantinib
Metastatic Colorectal Cancer
exatecan mesylate
Esophageal Cancer
ofloxacin otic
Otitis Media
Denosumab
Osteoporosis
Colesevelam HCl
Type 2 Diabetes
DS-1062a
Non-small Cell Lung Cancer
CPT-11 and TS-1
Colorectal Cancer
Dato-DXd
Urothelial Cancer
gemcitabine hydrochloride
Pancreatic Cancer
Warfarin Potassium
CTEPH
Hydrochlorothiazide
Hypertension
prasugrel
Diabetes Mellitus
Quizartinib
Leukemia
Pemetrexed
Metastatic Non Small Cell Lung Cancer
Pioglitazone
Type 2 Diabetes Mellitus
Low molecular weight heparin
Venous Thromboembolism (VTE)
warfarin tablets
Stroke
Etoposide
Non-small Cell Lung Cancer
Clopidogrel
Peripheral Arterial Disease
Pregabalin
Pain Associated With Fibromyalgia
Nab-paclitaxel
Breast Cancer
Datopotamab Deruxtecan
Metastatic Non Small Cell Lung Cancer
DS-8201a
Neoplasm, Gastrointestinal
Pexidartinib
Tenosynovial Giant Cell Tumor
edoxaban
Prevention
DS-5565
Pain Associated With Fibromyalgia
Trastuzumab Deruxtecan
Gastric Cancer
olmesartan medoxomil + hydrochlorothiazide, if necessary
Essential Hypertension
Ramucirumab
Non-Small Cell Lung Cancer
OM 40
Hypertension
CS-3150
Essential Hypertension
OM/HCTZ 40/12.5
Hypertension
Welchol
Type 2 Diabetes Mellitus
DU-176b
Venous Thromboembolism
CS-8958
Influenza, Human
Patritumab Deruxtecan
Nonsquamous Non-small Cell Lung Cancer
Trastuzumab deruxtecan (DS-8201a)
Breast Cancer
olmesartan medoxomil + hydrochlorothiazide
Essential Hypertension
Ifinatamab deruxtecan
Esophageal Squamous Cell Carcinoma
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)
Essential Hypertension
Trastuzumab deruxtecan (T-DXd)
Breast Cancer
Eplerenone
Essential Hypertension
Chemotherapy
Acute Myeloid Leukemia
Vitamin K antagonist
Atrial Fibrillation
Dalteparin
Venous Thromboembolism (VTE)
Mirogabalin
Diabetic Peripheral Neuropathic Pain
Eribulin
Breast Cancer
R-DXd
Solid Cancer
Amrubicin
Small Cell Lung Cancer
Olmesartan medoxomil plus amlodipine
Hypertension
Edoxaban-based Regimen
Atrial Fibrillation
Transdermal Patch
Trauma
nitrendipine + hydrochlorothiazide, if necessary
Isolated Systolic Hypertension
ASA
SCAD
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets
Essential Hypertension
Eribulin mesylate
Breast Cancer
Metformin HCl tablets and Colesevelam tablets
Type 2 Diabetes Mellitus
Colesevelam hydrochloride
Type 2 Diabetes
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets
Essential Hypertension
olmesartan medoxomil/hydrochlorothiazide tablets
Essential Hypertension
Platinum Chemotherapy
Non-small Cell Lung Cancer
Edoxaban tablets (low dose regimen-30mg)
Stroke
Edoxaban tablets (high dose regimen-60mg)
Stroke
Olmesartan medoxomil - Amlodipine
Essential Hypertension
Olmesartan medoxomil tablets high dose
Metabolic Syndrome
DU-176b (edoxaban)
Venous Thromboembolism
VKA-Based Regimen
Atrial Fibrillation
losartan potassium
Essential Hypertension
Olmesartan medoxomil tablets low dose
Metabolic Syndrome
T-DM1
HER2-Positive Primary Breast Cancer
Colesevelam
Type 2 Diabetes
edoxaban tosylate(DU-176b)
Venous Thromboembolism
Olmesartan medoxomil
Atherosclerosis
olmesartan medoxomil + amlodipine
Essential Hypertension
I-DXd
Oesophageal Squamous Cell Carcinoma
Combination drug
Hematological Malignancies
Patritumab Deruxtecan (Fixed dose)
Non-Small Cell Lung Cancer Metastatic
Carperitide
Heart Failure, Congestive
DS-5670a
Covid19
DU-176b tablets
Atrial Fibrillation
soblidotin
Lung Cancer
VN-0200
Respiratory Syncytial Virus Infections
DS-3939a
Advanced Solid Tumor
Valemetostat Tosylate
Adult T-cell Leukemia/Lymphoma
Quizartinib High Dose
Acute Myeloid Leukemia
DS-1040b
Acute Ischemic Stroke
DS-1001b
WHO Grade II Glioma
AC220
Leukemia, Myeloid, Acute
Compound AC220
Acute Myeloid Leukemia
Ifinatamab deruxtecan (I-DXd)
Advanced Solid Tumor
CS-1008 (humanized anti-DR5 antibody)
Pancreatic Cancer
DJ-927
Colorectal Cancer
U3-1287
NSCLC (Advanced Non-small Cell Lung Cancer)
PLX3397
Hodgkin Lymphoma
Rivoglitazone HCl
Type 2 Diabetes
Raludotatug deruxtecan
Advanced Solid Tumor
CS7017 tablets
Metastatic Non-small Cell Lung Cancer
DS-1211b
Pseudoxanthoma Elasticum
Pactimibe, CS-505
Coronary Heart Disease
CS7017
Colorectal Cancer
Warfarin potassium tablets
Atrial Fibrillation
edoxaban tosylate
Deep Vein Thrombosis
SUN13837 injection
Acute Spinal Cord Injury
Edoxaban (DU-176b)
Atrial Fibrillation
CS-1008
Non-small Cell Lung Cancer
HER3-DXd
Advanced Solid Tumor
DS-7011a
Systemic Lupus Erythematosus
ASB17061
Atopic Dermatitis
piclozotan
Parkinson's Disease
coformulation favezelimab/pembrolizumab
Small Cell Lung Carcinoma
MK-2010
Ovarian Cancer Recurrent
SUN13834
Atopic Dermatitis
DS-5141b
Duchenne Muscular Dystrophy
CS-917
Diabetes Mellitus, Type 2
DS-5565 tablet
Diabetic Peripheral Neuropathy
DS-1103a
Solid Tumor
Quizartinib Low Dose
Acute Myeloid Leukemia
DS3790a
Hematological Malignancies
SUN11031
Cachexia
DS-8500a
Type 2 Diabetes Mellitus
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Thrombosis
Trastzumab Deruxtecan
Ovarian Cancer
U3-1402
Metastatic Breast Cancer
Abraxane + Tigatuzumab
Breast Cancer
Pregabalin capsules
Pain
FOLFOX
Malignant Solid Tumour
Trastuzumab deruxtecan + 5FU/LV
Esophagogastric Adenocarcinoma
Trastuzumab deruxtecan + FLO
Esophagogastric Adenocarcinoma
5-hydroxytryptamine subtype 3 receptor antagonist
Carcinoma, Non-Small-Cell Lung
Pharmacological intensification based on olmesartan
Ischemic Stroke
Enhertu
Prostate Cancer Metastatic
Valemetostat
Lymphoma
Neurokinin-1 receptor antagonist
Carcinoma, Non-Small-Cell Lung
Boserolimab
Carcinoma, Non-Small-Cell Lung
Patritumab Deruxtecan (Up-Titration)
Non-Small Cell Lung Cancer Metastatic
Vibostolimab
Carcinoma, Non-Small-Cell Lung
MK-4830
Carcinoma, Non-Small-Cell Lung
Sitagliptin
Type 2 Diabetes Mellitus
Trastuzumab Deruxtecan (T-DXd) monotherapy
Gastric Adenocarcinoma
T-DXd, Durvalumab and Capecitabine Combination
Gastric Adenocarcinoma
Rescue Medications
Gastroesophageal Junction
89Zr-Patritumab deruxtecan
Non-Small Cell Lung Carcinoma
Abraxane alone
Breast Cancer
efatutazone
Anaplastic Thyroid Cancer
MK-1084
Lung Neoplasm Malignant
Gocatamig
Small Cell Lung Cancer Extensive Stage
Intrathecal (IT) triple chemotherapy prophylaxis
Acute Myeloid Leukemia
Dexrazoxane
Acute Myeloid Leukemia in Children
irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Colorectal Cancer
CS-7017
Advanced Non-small Cell Lung Cancer (NSCLC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Salvage Chemotherapy | Phase 3 | AML | - | - |
olmesartan medoxomil + amlodipine + hydroclororthiazide | Phase 3 | Essential Hypertension | - | - |
OLM -AML -Hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
Olmesartan -Amlodipine -Hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
cevimeline hydrochloride | Phase 3 | Head and Neck Cancer | - | - |
low molecular weight heparin/unfractionated heparin | Phase 3 | Venous Thromboembolism | - | - |
enoxaparin sodium | Phase 3 | Venous Thromboembolism | - | - |
CHS-0214 | Phase 3 | Rheumatoid Arthritis | - | - |
T-DXd | Phase 3 | Advanced Cancer | - | - |
Rivoglitazone | Phase 3 | Type 2 Diabetes | - | - |
Tivantinib | Phase 3 | Metastatic Colorectal Cancer | - | - |
exatecan mesylate | Phase 3 | Esophageal Cancer | - | - |
ofloxacin otic | Phase 3 | Otitis Media | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
Colesevelam HCl | Phase 3 | Type 2 Diabetes | - | - |
DS-1062a | Phase 3 | Non-small Cell Lung Cancer | - | - |
CPT-11 and TS-1 | Phase 3 | Colorectal Cancer | - | - |
Dato-DXd | Phase 3 | Urothelial Cancer | - | - |
gemcitabine hydrochloride | Phase 3 | Pancreatic Cancer | - | - |
Warfarin Potassium | Phase 3 | CTEPH | - | - |
Hydrochlorothiazide | Phase 3 | Hypertension | - | - |
prasugrel | Phase 3 | Diabetes Mellitus | - | - |
Quizartinib | Phase 3 | Leukemia | - | - |
Pemetrexed | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Low molecular weight heparin | Phase 3 | Venous Thromboembolism (VTE) | - | - |
warfarin tablets | Phase 3 | Stroke | - | - |
Etoposide | Phase 3 | Non-small Cell Lung Cancer | - | - |
Clopidogrel | Phase 3 | Peripheral Arterial Disease | - | - |
Pregabalin | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Nab-paclitaxel | Phase 3 | Breast Cancer | - | - |
Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
DS-8201a | Phase 3 | Neoplasm, Gastrointestinal | - | - |
Pexidartinib | Phase 3 | Tenosynovial Giant Cell Tumor | - | - |
edoxaban | Phase 3 | Prevention | - | - |
DS-5565 | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Trastuzumab Deruxtecan | Phase 3 | Gastric Cancer | - | - |
olmesartan medoxomil + hydrochlorothiazide, if necessary | Phase 3 | Essential Hypertension | - | - |
Ramucirumab | Phase 3 | Non-Small Cell Lung Cancer | - | - |
OM 40 | Phase 3 | Hypertension | - | - |
CS-3150 | Phase 3 | Essential Hypertension | - | - |
OM/HCTZ 40/12.5 | Phase 3 | Hypertension | - | - |
Welchol | Phase 3 | Type 2 Diabetes Mellitus | - | - |
DU-176b | Phase 3 | Venous Thromboembolism | - | - |
CS-8958 | Phase 3 | Influenza, Human | - | - |
Patritumab Deruxtecan | Phase 3 | Nonsquamous Non-small Cell Lung Cancer | - | - |
Trastuzumab deruxtecan (DS-8201a) | Phase 3 | Breast Cancer | - | - |
olmesartan medoxomil + hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
Ifinatamab deruxtecan | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) | Phase 3 | Essential Hypertension | - | - |
Trastuzumab deruxtecan (T-DXd) | Phase 3 | Breast Cancer | - | - |
Eplerenone | Phase 3 | Essential Hypertension | - | - |
Chemotherapy | Phase 3 | Acute Myeloid Leukemia | - | - |
Vitamin K antagonist | Phase 3 | Atrial Fibrillation | - | - |
Dalteparin | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Mirogabalin | Phase 3 | Diabetic Peripheral Neuropathic Pain | - | - |
Eribulin | Phase 3 | Breast Cancer | - | - |
R-DXd | Phase 3 | Solid Cancer | - | - |
Amrubicin | Phase 3 | Small Cell Lung Cancer | - | - |
Olmesartan medoxomil plus amlodipine | Phase 3 | Hypertension | - | - |
Edoxaban-based Regimen | Phase 3 | Atrial Fibrillation | - | - |
Transdermal Patch | Phase 3 | Trauma | - | - |
nitrendipine + hydrochlorothiazide, if necessary | Phase 3 | Isolated Systolic Hypertension | - | - |
ASA | Phase 3 | SCAD | - | - |
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets | Phase 3 | Essential Hypertension | - | - |
Eribulin mesylate | Phase 3 | Breast Cancer | - | - |
Metformin HCl tablets and Colesevelam tablets | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Colesevelam hydrochloride | Phase 3 | Type 2 Diabetes | - | - |
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets | Phase 3 | Essential Hypertension | - | - |
olmesartan medoxomil/hydrochlorothiazide tablets | Phase 3 | Essential Hypertension | - | - |
Platinum Chemotherapy | Phase 3 | Non-small Cell Lung Cancer | - | - |
Edoxaban tablets (low dose regimen-30mg) | Phase 3 | Stroke | - | - |
Edoxaban tablets (high dose regimen-60mg) | Phase 3 | Stroke | - | - |
Olmesartan medoxomil - Amlodipine | Phase 3 | Essential Hypertension | - | - |
Olmesartan medoxomil tablets high dose | Phase 3 | Metabolic Syndrome | - | - |
DU-176b (edoxaban) | Phase 3 | Venous Thromboembolism | - | - |
VKA-Based Regimen | Phase 3 | Atrial Fibrillation | - | - |
losartan potassium | Phase 3 | Essential Hypertension | - | - |
Olmesartan medoxomil tablets low dose | Phase 3 | Metabolic Syndrome | - | - |
T-DM1 | Phase 3 | HER2-Positive Primary Breast Cancer | - | - |
Colesevelam | Phase 3 | Type 2 Diabetes | - | - |
edoxaban tosylate(DU-176b) | Phase 3 | Venous Thromboembolism | - | - |
Olmesartan medoxomil | Phase 3 | Atherosclerosis | - | - |
olmesartan medoxomil + amlodipine | Phase 3 | Essential Hypertension | - | - |
I-DXd | Phase 2 | Oesophageal Squamous Cell Carcinoma | - | - |
Combination drug | Phase 2 | Hematological Malignancies | - | - |
Patritumab Deruxtecan (Fixed dose) | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Carperitide | Phase 2 | Heart Failure, Congestive | - | - |
DS-5670a | Phase 2 | Covid19 | - | - |
DU-176b tablets | Phase 2 | Atrial Fibrillation | - | - |
soblidotin | Phase 2 | Lung Cancer | - | - |
VN-0200 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
DS-3939a | Phase 2 | Advanced Solid Tumor | - | - |
Valemetostat Tosylate | Phase 2 | Adult T-cell Leukemia/Lymphoma | - | - |
Quizartinib High Dose | Phase 2 | Acute Myeloid Leukemia | - | - |
DS-1040b | Phase 2 | Acute Ischemic Stroke | - | - |
DS-1001b | Phase 2 | WHO Grade II Glioma | - | - |
AC220 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Compound AC220 | Phase 2 | Acute Myeloid Leukemia | - | - |
Ifinatamab deruxtecan (I-DXd) | Phase 2 | Advanced Solid Tumor | - | - |
CS-1008 (humanized anti-DR5 antibody) | Phase 2 | Pancreatic Cancer | - | - |
DJ-927 | Phase 2 | Colorectal Cancer | - | - |
U3-1287 | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | - | - |
PLX3397 | Phase 2 | Hodgkin Lymphoma | - | - |
Rivoglitazone HCl | Phase 2 | Type 2 Diabetes | - | - |
Raludotatug deruxtecan | Phase 2 | Advanced Solid Tumor | - | - |
CS7017 tablets | Phase 2 | Metastatic Non-small Cell Lung Cancer | - | - |
DS-1211b | Phase 2 | Pseudoxanthoma Elasticum | - | - |
Pactimibe, CS-505 | Phase 2 | Coronary Heart Disease | - | - |
CS7017 | Phase 2 | Colorectal Cancer | - | - |
Warfarin potassium tablets | Phase 2 | Atrial Fibrillation | - | - |
edoxaban tosylate | Phase 2 | Deep Vein Thrombosis | - | - |
SUN13837 injection | Phase 2 | Acute Spinal Cord Injury | - | - |
Edoxaban (DU-176b) | Phase 2 | Atrial Fibrillation | - | - |
CS-1008 | Phase 2 | Non-small Cell Lung Cancer | - | - |
HER3-DXd | Phase 2 | Advanced Solid Tumor | - | - |
DS-7011a | Phase 2 | Systemic Lupus Erythematosus | - | - |
ASB17061 | Phase 2 | Atopic Dermatitis | - | - |
piclozotan | Phase 2 | Parkinson's Disease | - | - |
coformulation favezelimab/pembrolizumab | Phase 2 | Small Cell Lung Carcinoma | - | - |
MK-2010 | Phase 2 | Ovarian Cancer Recurrent | - | - |
SUN13834 | Phase 2 | Atopic Dermatitis | - | - |
DS-5141b | Phase 2 | Duchenne Muscular Dystrophy | - | - |
CS-917 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
DS-5565 tablet | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
DS-1103a | Phase 2 | Solid Tumor | - | - |
Quizartinib Low Dose | Phase 2 | Acute Myeloid Leukemia | - | - |
DS3790a | Phase 2 | Hematological Malignancies | - | - |
SUN11031 | Phase 2 | Cachexia | - | - |
DS-8500a | Phase 2 | Type 2 Diabetes Mellitus | - | - |
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor | Phase 2 | Thrombosis | - | - |
Trastzumab Deruxtecan | Phase 2 | Ovarian Cancer | - | - |
U3-1402 | Phase 2 | Metastatic Breast Cancer | - | - |
Abraxane + Tigatuzumab | Phase 2 | Breast Cancer | - | - |
Pregabalin capsules | Phase 2 | Pain | - | - |
FOLFOX | Phase 2 | Malignant Solid Tumour | - | - |
Trastuzumab deruxtecan + 5FU/LV | Phase 2 | Esophagogastric Adenocarcinoma | - | - |
Trastuzumab deruxtecan + FLO | Phase 2 | Esophagogastric Adenocarcinoma | - | - |
5-hydroxytryptamine subtype 3 receptor antagonist | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Pharmacological intensification based on olmesartan | Phase 2 | Ischemic Stroke | - | - |
Enhertu | Phase 2 | Prostate Cancer Metastatic | - | - |
Valemetostat | Phase 2 | Lymphoma | - | - |
Neurokinin-1 receptor antagonist | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Boserolimab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Patritumab Deruxtecan (Up-Titration) | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Vibostolimab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
MK-4830 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Sitagliptin | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Trastuzumab Deruxtecan (T-DXd) monotherapy | Phase 2 | Gastric Adenocarcinoma | - | - |
T-DXd, Durvalumab and Capecitabine Combination | Phase 2 | Gastric Adenocarcinoma | - | - |
Rescue Medications | Phase 2 | Gastroesophageal Junction | - | - |
89Zr-Patritumab deruxtecan | Phase 2 | Non-Small Cell Lung Carcinoma | - | - |
Abraxane alone | Phase 2 | Breast Cancer | - | - |
efatutazone | Phase 2 | Anaplastic Thyroid Cancer | - | - |
MK-1084 | Phase 2 | Lung Neoplasm Malignant | - | - |
Gocatamig | Phase 2 | Small Cell Lung Cancer Extensive Stage | - | - |
Intrathecal (IT) triple chemotherapy prophylaxis | Phase 2 | Acute Myeloid Leukemia | - | - |
Dexrazoxane | Phase 2 | Acute Myeloid Leukemia in Children | - | - |
irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI) | Phase 2 | Colorectal Cancer | - | - |
CS-7017 | Phase 2 | Advanced Non-small Cell Lung Cancer (NSCLC) | - | - |
Advanced solid tumors
1 drug in this indication
tenosynovial giant cell tumours
1 drug in this indication
First-line metastatic breast cancer
1 drug in this indication
HER2-low metastatic breast cancer
1 drug in this indication
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
1 drug in this indication
Previously treated extensive-stage small cell lung cancer
1 drug in this indication
Multiple tumor types
1 drug in this indication
Advanced or metastatic solid tumours
1 drug in this indication
Dyslipidemia and cardiovascular risk
1 drug in this indication
Adjuvant treatment for HER2 positive early breast cancer with residual disease after neoadjuvant treatment
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Daiichi Sankyo's drug pipeline?→
CatalystAlert tracks 160 drug candidates in Daiichi Sankyo's (DSKYF) pipeline across Phase 3, Phase 2. Its lead program is Trastuzumab Deruxtecan (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Daiichi Sankyo's next FDA catalyst?→
Daiichi Sankyo's (DSKYF) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DSKYF biotech catalysts?→
Add DSKYF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Daiichi Sankyo's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
